Professor Ma Jun and Zhu Jun: The new anti-CD20 monoclonal antibody repatitumab has been heavily marketed, adding new strength to the treatment of lymphoma

With the continuous emergence of new drugs and the entry into the clinic, the overall survival status of lymphoma patients has been significantly improved, and the treatment mode of anti-CD20 monoclonal antibody combined with chemotherapy has become the first-line treatment standard for

However, there is still a big gap between the treatment of lymphoma in China and European and American countries, and at present, only relatively developed areas such as Beijing, Shanghai, Guangzhou, and central hospitals have a five-year disease-free survival rate of about 62%, which is about the same as that of European and American countries (about 72% in the United States).

Medical pulse communication: Targeted drugs occupy an important position in lymphoma treatment, and the combination treatment scheme based on anti-CD20 monoclonal antibody has become the gold standard for first-line treatment of B-cell lymphoma such as DLBCL and FL

* ADR: adverse reactions; AE: adverse events

Medical Pulse Pass: The field of lymphoma treatment is developing with each passing day, can you please look forward to the development prospects of this field? What are your expectations for innovative biopharmaceutical companies in China?

The ability to innovate is crucial, and without the advent of innovative drugs, there is no cure
for malignant tumors.

Although China has become the world's second largest economy after the United States, it is still in the third world in terms of drug innovation, and it may be ten years, twenty years or even more away from the goal of the gradual reduction of Me Too and Me Better drugs and the gradual increase of First in Class drugs
.

There are three key principles of drug innovation, namely: (1) China's pharmaceutical companies need to increase investment in new drug research and development, reaching 10% or more of annual revenue; (2) Continuous research and development of First in Class drugs; (3) Strengthen the cultivation of clinical research teams, among the top clinical research teams in the world, MD Anderson Cancer Center in the United States occupies more than 160, while the sum of China's tumor and blood fields does not reach 30
.

Following these three principles will inevitably usher in the era of
China's First in Class.

In addition to the new anti-CD20 monoclonal antibody, Shenzhou Cell's innovative drugs also include recombinant human coagulation factor VIII.
, which has been applied to the treatment of hemophilia, and the price is very close to the people
.

It is believed that Shenzhou Cell has the ability to develop more innovative drugs for anti-tumor targets, serve hematological tumors and other malignant tumors, promote China's innovative drugs to the forefront of the world, and hope that Shenzhou Cells will achieve more achievements under the guidance of scientists and clinical experts and strive to become a world-class biopharmaceutical company
.

In the past 20 years, China's lymphoma treatment has made great progress, and in many large lymphoma centers and hematological tumor centers in large cities, the five-year disease-free survival rate of patients has been significantly improved
.

For example, in the lymphoma department of Peking University Cancer Hospital, the five-year disease-free survival rate of patients has reached about 65%, of which classical Hodgkin lymphoma has increased to more than
80%.

In the future, we will follow the basic principles and routes of standardized diagnosis and treatment, strengthen the development of specialized diseases, multidisciplinary cooperation and the whole health management of lymphoma patients, and witness the continuous emergence of new drugs and new programs in the new era to bring more clinical benefits
to patients.

I believe that with the development of national science and technology, medical research, medical technology and innovative drugs, China's lymphoma patients have more hope for a cure, and I also believe that with the joint efforts of their counterparts across the country, we will be able to achieve the goal of cancer prevention and control in the "Healthy China 2030" Planning Outline!

Professor Ma Jun

• Chief physician, professor, doctoral supervisor

• Director of Harbin Institute of Hematology and Oncology

• Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO).
  

• Vice Chairman of the Asian Society of Clinical Oncology

• President of the CSCO Anti-Leukemia Alliance

• Former Vice Chairman of the Hematology Branch of the Chinese Medical Association

• Vice President of the Hematology Branch of the Chinese Medical Doctor Association

• Vice President of Oncology Branch of Chinese Medical Doctor Association

• Past President of the CSCO Anti-Lymphoma Alliance

• In 1979, he went to the Faculty of Medicine, the University of Tokyo, Japan, and has been committed to the diagnosis and treatment of benign and malignant diseases of the blood system, especially in the treatment of leukemia and lymphoma

• In 1982, the in vitro pluripotent hematopoietic progenitor cell culture system was first established in China to fill the domestic gap

• Since 1983, more than 1,200 cases of acute promyelocytic leukemia have been treated with retinoic acid and arsenic trioxide sequential therapy, with a 10-year disease-free survival rate of 85%, reaching the international advanced level

• He has published more than 200 papers and more than 40 monographs in domestic and foreign journals, and won 20 national, provincial and municipal science and technology awards

• He has undertaken 8 major national 863 scientific research projects and 25 provincial and municipal scientific research projects

Professor Zhu Jun

• Secretary of the Party Committee of Peking University Cancer Hospital

• Director of the Department of Internal Medicine, Director of the Department of Lymphoma, Doctoral Supervisor

• Executive Director of the Council of the Chinese Society of Clinical Oncology (CSCO).
  

• Vice Chairman of Beijing Heathco Clinical Oncology Research Foundation

• Chairman of the CSCO Lymphoma Expert Committee

• Member of the Standing Committee of the Geriatric Oncology Professional Committee of the Chinese Gerontology Society

• He is the chairman of the Oncology Branch of Beijing Medical Association

• Vice Chairman of Beijing Anti-Cancer Association

• President of the Chinese Health Science and Technology Promotion Association

References:

1.
Shi, Qingyuan Zhang, Xiaonan Hong, et al .
Hematol Oncol.
2022 Jul 20.

Poke "Read the original article" to see more